| Trial ID: | L2000 |
| Source ID: | NCT04585776
|
| Associated Drug: |
Ly900014
|
| Title: |
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT04585776/results
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: LY900014|DRUG: Insulin Degludec
|
| Outcome Measures: |
Primary: Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) With Continuous Glucose Monitoring (CGM), Percentage of Time with Sensor Glucose Values Between 70 and 180 mg/dL (both inclusive) with CGM., Day 46 | Secondary: Insulin to Carbohydrate Ratio (ICR), ICR was evaluated to estimate how many carbohydrates will be covered by one unit of insulin., Day 46|Ratio of Prandial Dose to Total Daily Dose (TDD) of Insulin, Prandial:TDD ratio, Day 46|Product of Insulin to Carbohydrate Ratio and Total Daily Dose (ICR×TDD), ICR×TDD is determined to evaluate the relationship between insulin to carbohydrate ratio (g/U) and the total daily insulin dose (U/day)., Day 46
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
31
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-10-30
|
| Completion Date: |
2021-05-27
|
| Results First Posted: |
2022-06-03
|
| Last Update Posted: |
2022-06-03
|
| Locations: |
Atlanta Diabetes Associates, Atlanta, Georgia, 30318, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, 50265, United States|HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota, 55416, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04585776
|
